FORMULATION AND EVALUATION OF METFORMIN HYDROCHLORIDE AND GLICLAZIDE SUSTAINED RELEASE BILAYER TABLETS: A COMBINATION THERAPY IN MANAGEMENT OF DIABETES
Keywords:Bilayer tablet, Sustained-release, Metformin hydrochloride, Gliclazide and type 2 diabetes mellitus
Objective: The main objective of the present investigation is to develop a sustained-release (SR) formulation to optimize the postprandial elevation of glucose level in type 2 Diabetic subjects using combination therapy. In the present research work, bilayer sustained release formulation of metformin hydrochloride (MFH) and gliclazide (GLZ), based on monolithic-matrix technology was developed and evaluated.
Methods: The formulations of metformin hydrochloride layer and gliclazide layer that contain polyox WSR coagulant and different viscosity grades of hydroxyl propyl methylcellulose (HPMC) as sustained-release matrix were prepared by direct compression and wet granulation method respectively. The bilayer tablets were prepared after carrying out the optimization of metformin layer and evaluated for various pre-compression and post-compression parameters. For the best formulation selected on basis of in vitro evaluation of tablets, Fourier-transform infrared spectroscopy (FT-IR) studies and comparison of in vitro dissolution profile of developed formulation with the innovator were performed.
Results: Metformin hydrochloride and gliclazide showed sustained release of drug by diffusion mechanism and followed first-order kinetics. The best formulation of metformin hydrochloride (M7) and gliclazide (G8) show 99.93% and 99.65% of drug release in 24 h respectively. The similarity factor (f2) was 79.95 for metformin hydrochloride and 73.62 for gliclazide when compared with the innovator.
Conclusion: The monolith diffusion-controlled bilayer tablets of metformin hydrochloride and gliclazide offer improved patient compliance and convenience with better postprandial hyperglycemic control with once-a-day dosing. The sustained release of the drug up to 24 h regulate antidiabetic activity round the clock with minimal side effects.
Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. Goodman and gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw Hill; 2011.
Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol 2016;12:357-70.
Rajni J, Piyush J, Poorva J. A review on treatment and prevention of diabetes mellitus. Int J Curr Pharm Res 2016;8:16-8.
International Diabetes Federation. Atlas of Diabetes. 5th ed. Belgium: International Diabetes Federation; 2011.
World Health Organization Global report on diabetes 2016.
International Diabetes Federation, IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017. Available from: http://www.diabetesatlas.org. [Last accessed on 23 Jan 2019]
Jadhav VD, Patil JR, Patil PP. Formulation and evaluation of bilayered tablet of piracetam and vinpocetine. J Chem Pharm Res 2011;3:423-31.
Shiyani B, Gattani S, Surana S. Formulation and evaluation of bilayer tablet of metoclopramide hydrochloride and ibuprofen. AAPS PharmSciTech 2008;9:818-27.
Rashmi MB, Prakash R, Abbulu K, Sudarshan S, Nawres A Taha, Suresh C. Statistical design and development of a liquid oral floating in situ gel of metformin hydrochloride for sustained release: pharmacodynamics and toxicity (histopathology) studies. Int J Appl Pharm 2019;11:96-104.
Park K. Controlled drug delivery systems: past forward and future back. J Controlled Release 2014;190:3-8.
Al-Omary FA. Gliclazide. Profiles Drug Subst Excipients Relat Methodol 2017;42:125-92.
Vishwakarma AG, Pawar AY, Mogal RT. Bilayer tablet-a new ways in oral drug delivery system. Int J Pharm Tech Res 2014;6:1416-28.
Lieberman HA, Lachman L. Pharmaceutical dosage form. Vol. 1. New York: 2nd edition CRC Press; 1989.
Rahul S Solunke, Uday RB, Krishna M, Madhuri T Deshmukh, Raj Kumar V Shete. Formulation and evaluation of gliclazide nanosponges. Int J Appl Pharm 2019;116:181-9.
Wadher KJ, Kakde RB, Umekar MJ. Formulation and evaluation of sustained-release tablets of metformin hydrochloride using hydrophilic synthetic and hydrophobic natural polymers. Indian J Pharm Sci 2011;73:208-15.
Purushottam, Gangane S, Manish M Kadam, Debarshi KM, Nilesh M, Mahajan U, et al. Design and formulating gliclazide solid dispersion immediate-release layer and metformin sustained release layer in bilayer tablet for the effective postprandial management of diabetes mellitus. Int J Pharm Sci Res 2018;9:3743-56.
Nanjwade BG, Manvi FZ. Formulation of extended-release metformin hydrochloride matrix tablets. Trop J Pharm Res 2011;10:375-83.
Indian Pharmacopoeia. Vol. 2. New Delhi: Controller of Publication, Govt. of India, Ministry of Health and Family Welfare; 1996. p. 736.
Kalpesh W, Sachin K, Kamlesh D Mali, Satish KP, Dheeraj TB. Design and evaluation of bilayer tablets of glimepiride and metformin hydrochloride with the combination of hydrophilic and hydrophobic polymers by hot-melt extrusion of bilayer tablets of glimepiride and metformin. Asian J Pharm Clin Res 2014;7:300-4.
Padmaja. Formulation and evaluation of metformin HCl sustained-release oral matrix tablets. Asian J Pharm Clin Res 2018;11:342-5.
Gandhimathi M, Ananda KK, Cheriyan A, Ravi TK. Simultaneous estimation of metformin and gliclazide in tablets using reverse phase high-performance liquid chromatography. Indian J Pharm Sci 2003;65:530-1.
Ediga S. A new simple RP–HPLC method for simultaneous estimation of metformin HCl and gliclazide tablet dosage form. Int J Pharm Biol Sci 2012;2:277-83.
Higuchi TA. Mechanism of sustained action medication. J Pharm Sci 1963;52:1145-9.
Sudipta D, Arnab S, Himadri SDE. Formulation, in vitro release kinetics and stability interpretation of sustained-release tablets of metformin hydrochloride. Int J Pharm Pharm Sci 2015;7:418-22.
Mathews BA. Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm 1999;25:831-56.
Santhosh K, Bhagwat P, Prachi U. Bilayer tablet of tramadol and gabapentin for combination pharmacotherapy of neuropathic pain: development and characterization. Int J Appl Pharm 2018;10:100-7.
How to Cite
Copyright (c) 2021 Rajeswari Aleti
This work is licensed under a Creative Commons Attribution 4.0 International License.